Bizarre Patents
A method for inducing cats to exercise consists of directing a beam of invisible light produced by a hand-held laser apparatus onto the floor or wall.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120108573 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM The present invention relates to compounds of the formula I wherein A1, A2, R1, R3, X and n are as defined in the claims, which are valuable pharmaceutically active... | 05/03/2012 |
| 20120108642 | TRPV1 ANTAGONISTS The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4, R5, m, and n are defined in the specification are TRPV1 antagonists.... | 05/03/2012 |
| 20120071519 | CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR Provided herein are crystalline forms of a maleate salt of betrixaban, compositions and methods of preparation or use thereof.... | 03/22/2012 |
| 20120052118 | Apparatus and process for encapsulating capsules or other solid dosage forms within capsules The present invention provides an apparatus and process for making softgel capsules having incorporated therein other solid dosage forms selected from the group consisting of pellets, smaller capsules, smaller tablets, sustained release solid dosage forms, immediate rel... | 03/01/2012 |
| 20120052122 | Treatment Of Chronic Obstructive Pulmonary Disease With Phosphodiesterase-4 Inhibitor Disclosed is a method of treatment of chronic obstructive pulmonary disease associated with chronic bronchitis in a patient at risk of exacerbations. The method includes administering to a patient with a history of chronic obstructive pulmonary disease associated with c... | 03/01/2012 |
| 20120052055 | METHOD OF TREATING THROMBOCYTOPENIA Invented is a method of treating thrombocytopenia in a human, in need thereof which comprises the in vivo administration of a therapeutically effective amount of a peptide or a non-peptide TPO receptor agonist and an anti-clotting agent or agents, and optional further a... | 03/01/2012 |
| 20120046243 | Aminopyridine- and Aminopyrimidinecarboxamides as CXCR2 Modulators There is disclosed aminopyridine-and aminopyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include aminopyridine- and aminopyrimidinecarboxamides compounds. More specifically, there is disclosed ... | 02/23/2012 |
| 20120046230 | Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions... | 02/23/2012 |
| 20120041034 | SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet whic... | 02/16/2012 |
| 20120035217 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors There is provided compounds of formula I, wherein Y, ring A, D1, D2a, D2b, D3, L1, Y1, L2 and Y2 have meanings given in ... | 02/09/2012 |
| 20120029036 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF Disclosed are a composition comprising a pyridyl cyanoguanidine and a cyclodextrin, a cyclodextrin derivative and/or a surfactant with solubilization, process for preparing the same and use thereof.... | 02/02/2012 |
| 20120029035 | COMPOSITIONS AND METHODS FOR EXTENDED THERAPY WITH AMINOPYRIDINES Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, for use in a therapeutically effective manner for patients with a demyelinating condition, such as multiple sclerosis.... | 02/02/2012 |
| 20120028930 | FLUPIRTINE SALTS AND POLYMORPHS The present invention includes salts and polymorphs of flupirtine including, but not limited to carboxylic acid salts and sulfonic acid salts and their polymorphs. The present invention also includes pharmaceutical compositions comprising the salts and polymorphs of flu... | 02/02/2012 |
| 20120022070 | Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use Novel classes of molecular chaperone Heat shock protein 90 (Hsp90) inhibitors are disclosed. These compounds are useful in treating and preventing cancer and other Hsp90-related diseases and conditions, such as inflammation and neurodegenerative disorders. Methods of tr... | 01/26/2012 |
| 20120022116 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX Disclosed are compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically related to GPR35, and/or GPR35-hERG signaling complex. For example, disclosed are compounds for preventing and/or treating diseases which are pathophysi... | 01/26/2012 |
| 20120014918 | ADDITION SALTS OF AMINES CONTAINING HYDROXYL AND/OR CARBOXYLIC GROUPS WITH AMINO NICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS The present disclosure is directed to novel water-soluble pharmaceutically acceptable, crystalline addition salts of (i) an amine containing one or more hydroxyl and/or carboxylic groups with (ii) amino nicotinic acid derivatives of formula (I) 01/19/2012 | |
| 20120015943 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF This invention provides compounds of formula (I):
| 01/19/2012 |
| 20120015967 | PYRIMIDINE AND PYRIDINE DERIVATIVES AS POSH AND POSH-AP INHIBITORS Pyridine and pyrimidine derivatives inhibit ubiquitination of human polypeptides, particularly of POSH and POSH-associated proteins such as HERPUD1, and can be used as medicaments for treatment of viral infections caused by virus such as HIV and for treatment of neurolo... | 01/19/2012 |
| 20120010196 | METHODS OF TREATING NEURODEGENERATIVE DISORDERS AND DISEASES This invention is directed to a novel method of treating neurodegenerative disorders and diseases. Another, related aspect of this invention is directed to a screening method of identifying compounds that can be used to treat neurodegenerative disorders and diseases. Th... | 01/12/2012 |
| 20120004244 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors There is provided compounds of formula I, wherein E1, E2a, E2b, E2c, E4, D1, D2, D3, L1, Y1, L | |
| 20120004228 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors There is provided compounds of formula I, wherein Y, ring A, Da, Db, D2, D3, L1, Y1, L2, Y2, L3 and Y3 <... | 01/05/2012 |
| 20110319431 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors There is provided compounds of formula I, wherein Y, ring A, D1, D2a, D2b, D3, L1, Y1, L3 and Y3 have meanings given in ... | 12/29/2011 |
| 20110319438 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS The invention is concerned with novel sulfonamide derivatives of formula (I) wherein R2, R3, R4, A, X, Y1, Y2, Y3, Y4 and Z1 <... | 12/29/2011 |
| 20110319454 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY The invention provides well defined compounds having FPRL-1 agonist or antagonist activity. As such, the compounds of the invention are useful for treating a variety of ocular disorders.... | 12/29/2011 |
| 20110312958 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The pres... | 12/22/2011 |
| 20110313005 | TOPICALLY APPLICABLE PHARMACEUTICAL PREPARATION A topical pharmaceutical preparation for administering a slightly soluble PDE4 inhibitor is described. A surprisingly good systemic bioavailability is observed with this dosage form.... | 12/22/2011 |
| 20110313000 | CCR9 INHIBITORS AND METHODS OF USE THEREOF The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds re... | 12/22/2011 |
| 20110301179 | NAPHTHAMIDES AS ANTICANCER AGENTS A compound (particularly useful for inhibiting cancer) according to formula I:
| 12/08/2011 |
| 20110293610 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR PROTEIN The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphoc... | 12/01/2011 |
| 20110281871 | TAAR1 LIGANDS The invention relates to a compound of formula wherein
11/17/2011 | |
| 20110275679 | FLUPIRTINE HYDROCHLORIDE MALEIC ACID COCRYSTAL The invention relates to crystalline forms of flupirtine, particularly to 1:1 flupirtine hydrochloride maleic acid cocrystal. The preparation and characterization of 1:1 flupirtine hydrochloride maleic acid cocrystal is described. The invention also relates to the thera... | 11/10/2011 |
| 20110269774 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R11, R12, R13, ... | 11/03/2011 |
| 20110269750 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS The application relates to specific combinations of Roflumilast and/or Roflumilast N-Oxide and a PPAR-agonist, as well as their use in the treatment of diabetes mellitus type 2.... | 11/03/2011 |
| 20110269724 | Combination Therapy with Non-Selective COX Inhibitors to Prevent COX-Related Gastric Injuries The present invention is directed to nicotinamide, nicotinamide derivatives and prostaglandin mimetics, alone or in combination with an NSAID, and their use in treating pain, inflammation, and/or gastrointestinal toxicty,... | 11/03/2011 |
| 20110262388 | NOVEL INHIBITORS Novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization ... | 10/27/2011 |
| 20110263601 | METHODS OF TREATING ULCERATIVE COLITIS Methods are disclosed for treating ulcerative colitis and related diseases and disorders, which comprise inhibiting tryptophan hydroxylase (TPH) in patients in need thereof.... | 10/27/2011 |
| 20110263556 | New Compounds This invention relates to compounds of formula I, their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medi... | 10/27/2011 |
| 20110263478 | SUR1 INHIBITORS FOR THERAPY Methods and compositions are provided that are utilized for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN). In particular, the methods and compositions are inhibitors of a particular NCca-ATP channel and include, for... | 10/27/2011 |
| 20110263585 | Screening Assay for Insecticides The present invention relates to polypeptides, preferably from Drosophila melanogaster (DmShaI) as target for insecticides.... | 10/27/2011 |
| 20110263612 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other co... | 10/27/2011 |
